Smith Micro 3Q 2026: Revenue $5.02M, EPS ($0.3) — 10-Q Summary

Smith Micro reported 3Q 2026 revenue of $5.02M, up 15% YoY, and narrowed net loss to $1.7M. Growth was driven by Family Safety and CommSuite products, with higher revenue and lower costs.

Original reporting
Published Nov 12, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Smith Micro 3Q 2026: Revenue $5.02M, EPS ($0.3) — 10-Q Summary — source image
Decision brief

The 30-second read

$SMSIBullishLow
01

Why it matters

The earnings release narrows the net loss and improves gross margin, which could attract value‑oriented traders looking for turnaround stories.

02

Market read

Micro‑cap earnings with loss improvement may trigger modest price movement, but limited liquidity caps broader market relevance.

03

What to watch

One‑time engineering fees contributed to revenue; future quarters may not repeat this boost.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Smith Micro Software (SMSI) is a small U.S. cybersecurity and connectivity solutions provider. The Q3 2026 10‑Q filing is the first public source of its latest earnings data.

Company-level read

Ticker impact

$SMSIBullishHigh confidence
Context

Smith Micro reported Q3 2026 revenue of $5.02M, a 15% YoY increase, and a narrowed net loss, marking the first public disclosure of these earnings figures.

Expected impact

likely modest upside as the market prices in the narrowed loss and revenue growth

Evidence & confidence

First‑report earnings numbers for a micro‑cap; loss improvement and margin expansion are positive catalysts, though absolute size is small.

Market effects

Shows continued demand for security‑software solutions, modestly supportive for the broader cybersecurity niche.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact given the company's size.

Counterpoint

Despite the loss narrowing, the company remains unprofitable and revenue is still under $10M, suggesting limited upside.

Key entities

  • Smith Micro Software, Inc.

    U.S. listed provider of security and connectivity software (ticker SMSI).

Related articles

$SMSIMed

Smith Micro Reports Third Quarter 2026 Financial Results

SMITH MICRO SOFTWARE, INC. (SMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IR INQUIRIES: Charles Messman Investor Relations 412-837-5300 IR@smithmicro.com Smith Micro Reports Third Quarter 2026 Financial Results PITTSBURGH, PA, November 12, 2026 – Smith Micro Software, Inc. ( Nasdaq: SMSI ) (“Smith Micro” or the “Company”) today reported fi

$SMSIMed

Smith Micro Reports Second Quarter 2026 Financial Results

SMITH MICRO SOFTWARE, INC. (SMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IR INQUIRIES: Charles Messman Investor Relations 412-837-5300 IR@smithmicro.com Smith Micro Reports Second Quarter 2026 Financial Results PITTSBURGH, PA, August 13, 2026 – Smith Micro Software, Inc. ( Nasdaq: SMSI ) (“Smith Micro” or the “Company”) today reported fin

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.